Loading
A phase 3 trial of Atezolizumab, Trastuzumab emtansine and Trastuzumab in HER2-positive breast cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy is a phase 3 interventional study registered as NCT04873362 by Hoffmann-La Roche, with 1188 participants enrolled, started 2021-05-04 and due to reach its primary completion in 2027-03-31. Interventions recorded: Atezolizumab, Trastuzumab Emtansine, Placebo and Trastuzumab.
Shares Flatiron Health (Roche), Trastuzumab emtansine, Atezolizumab, Trastuzumab and the tag pipeline.
Shares Trastuzumab emtansine, Early HER2-positive breast cancer, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Trastuzumab, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Monoclonal antibodies, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Early HER2-positive breast cancer, HER2-positive breast cancer, Monoclonal antibodies and the tag pipeline.
Shares Flatiron Health (Roche), Atezolizumab, Immune checkpoint inhibitors and the tag pipeline.